We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer.
- Authors
Braman, Nathaniel; Prasanna, Prateek; Whitney, Jon; Singh, Salendra; Beig, Niha; Etesami, Maryam; Bates, David D. B.; Gallagher, Katherine; Bloch, B. Nicolas; Vulchi, Manasa; Turk, Paulette; Bera, Kaustav; Abraham, Jame; Sikov, William M.; Somlo, George; Harris, Lyndsay N.; Gilmore, Hannah; Plecha, Donna; Varadan, Vinay; Madabhushi, Anant
- Abstract
Key Points: Question: Can quantitative imaging features extracted from the tumor and tumor environment on breast magnetic resonance imaging characterize tumor biological features relevant to outcome of targeted therapy? Findings: In this diagnostic study of 209 patients, among HER2 (ERBB2)-positive breast cancers, an intratumoral and peritumoral imaging signature capable of discriminating the response-associated HER2-enriched molecular subtype was identified. When evaluated among recipients of HER2-targeted therapy, this signature was found to be associated with response to neoadjuvant chemotherapy. Meaning: Quantitative analysis of the tumor and its surroundings may provide valuable cues into breast cancer biological features and likelihood of response to targeted therapy. Importance: There has been significant recent interest in understanding the utility of quantitative imaging to delineate breast cancer intrinsic biological factors and therapeutic response. No clinically accepted biomarkers are as yet available for estimation of response to human epidermal growth factor receptor 2 (currently known as ERBB2, but referred to as HER2 in this study)–targeted therapy in breast cancer. Objective: To determine whether imaging signatures on clinical breast magnetic resonance imaging (MRI) could noninvasively characterize HER2-positive tumor biological factors and estimate response to HER2-targeted neoadjuvant therapy. Design, Setting, and Participants: In a retrospective diagnostic study encompassing 209 patients with breast cancer, textural imaging features extracted within the tumor and annular peritumoral tissue regions on MRI were examined as a means to identify increasingly granular breast cancer subgroups relevant to therapeutic approach and response. First, among a cohort of 117 patients who received an MRI prior to neoadjuvant chemotherapy (NAC) at a single institution from April 27, 2012, through September 4, 2015, imaging features that distinguished HER2+ tumors from other receptor subtypes were identified. Next, among a cohort of 42 patients with HER2+ breast cancers with available MRI and RNaseq data accumulated from a multicenter, preoperative clinical trial (BrUOG 211B), a signature of the response-associated HER2-enriched (HER2-E) molecular subtype within HER2+ tumors (n = 42) was identified. The association of this signature with pathologic complete response was explored in 2 patient cohorts from different institutions, where all patients received HER2-targeted NAC (n = 28, n = 50). Finally, the association between significant peritumoral features and lymphocyte distribution was explored in patients within the BrUOG 211B trial who had corresponding biopsy hematoxylin-eosin–stained slide images. Data analysis was conducted from January 15, 2017, to February 14, 2019. Main Outcomes and Measures: Evaluation of imaging signatures by the area under the receiver operating characteristic curve (AUC) in identifying HER2+ molecular subtypes and distinguishing pathologic complete response (ypT0/is) to NAC with HER2-targeting. Results: In the 209 patients included (mean [SD] age, 51.1 [11.7] years), features from the peritumoral regions better discriminated HER2-E tumors (maximum AUC, 0.85; 95% CI, 0.79-0.90; 9-12 mm from the tumor) compared with intratumoral features (AUC, 0.76; 95% CI, 0.69-0.84). A classifier combining peritumoral and intratumoral features identified the HER2-E subtype (AUC, 0.89; 95% CI, 0.84-0.93) and was significantly associated with response to HER2-targeted therapy in both validation cohorts (AUC, 0.80; 95% CI, 0.61-0.98 and AUC, 0.69; 95% CI, 0.53-0.84). Features from the 0- to 3-mm peritumoral region were significantly associated with the density of tumor-infiltrating lymphocytes (R2 = 0.57; 95% CI, 0.39-0.75; P =.002). Conclusions and Relevance: A combination of peritumoral and intratumoral characteristics appears to identify intrinsic molecular subtypes of HER2+ breast cancers from imaging, offering insights into immune response within the peritumoral environment and suggesting potential benefit for treatment guidance. This diagnostic study examines the use of magnetic resonance imaging to identify tumor biological factors associated with targeted therapy response for HER2-positive breast cancer.
- Subjects
OHIO; BREAST tumor diagnosis; BREAST tumor treatment; CANCER chemotherapy; COMBINED modality therapy; CONFIDENCE intervals; ESTROGEN receptors; GENE expression; IMMUNOHISTOCHEMISTRY; MAGNETIC resonance imaging; ONCOGENES; PROGESTERONE receptors; DOCETAXEL; TRASTUZUMAB; HEALTH Insurance Portability &; Accountability Act; TREATMENT effectiveness; RETROSPECTIVE studies; RECEIVER operating characteristic curves; CARBOPLATIN
- Publication
JAMA Network Open, 2019, Vol 2, Issue 4, pe192561
- ISSN
2574-3805
- Publication type
Article
- DOI
10.1001/jamanetworkopen.2019.2561